Cirrhosis future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Overview
Cirrhosis is an irreversible change to the liver, and ongoing research hopes to determine the mechanism of scar formation and how to interrupt or reverse this process.[1] Newer therapies are being developed against viral causes of liver diseases. New vaccines are currently under development for Hepatitis C, and have already been developed for hepatitis B.
Future or Investigational Therapies
Future or Investigational Therapies
The following therapies are under trial:
- Obeticholic acid (OCA) for patients with primary biliary cirrhosis.[2]
- Boehringer Ingelheim’s investigational direct-acting antiviral compounds: BI 201335 (protease inhibitor) plus BI 207127 (polymerase inhibitor) for the treatment of Hepatitis C induced Cirrhosis.[3]
- Entecavir in decompensated Hepatitis B Viral cirrhosis.[4]
References
References
- ↑ Iredale JP (2003). “Cirrhosis: new research provides a basis for rational and targeted treatments”. BMJ. 327 (7407): 143–7. doi:10.1136/bmj.327.7407.143. PMC 1126509. PMID 12869458.
- ↑ Lindor KD (2011). “Farnesoid X receptor agonists for primary biliary cirrhosis”. Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.
- ↑ Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B; et al. (2011). “Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection”. Gastroenterology. 141 (6): 2047–55, quiz e14. doi:10.1053/j.gastro.2011.08.051. PMID 21925126.
- ↑ Fontana RJ (2010). “Entecavir in decompensated HBV cirrhosis: the future is looking brighter”. J Hepatol. 52 (2): 147–9. doi:10.1016/j.jhep.2009.10.025. PMID 20006400.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH